Navigation Links
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Date:8/28/2008

ward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to receive regulatory approval for its drug candidates, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners


'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
2. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
3. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
4. ThreeWire Expands Presence in the Pharmaceutical Arena
5. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
6. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
7. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
9. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
10. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Lawrence, MA (PRWEB) December 19, 2014 ... flow MRLAFMQ test for the Detection of Aflatoxin M1 ... test to receive independent third party validation. The peer ... Science Unit of the Institute for Agricultural and Fisheries ... Francis Group. , Aflatoxin B1, the most toxic ...
(Date:12/19/2014)... Ill. , Dec. 19, 2014 Naurex ... develop novel drugs for diseases of the central nervous ... president and chief executive officer, will present at the ... Riedel,s presentation will take place at 3:00 p.m. PST ... Francis in San Francisco, Calif. ...
(Date:12/19/2014)... Calif. , Dec. 19, 2014 Bina Technologies, ... USA) announced today that they have been acquired by ... is a privately held company that provides a ... next generation sequencing (NGS) data for the academic and ... Roche Sequencing Unit, and will continue to focus on ...
(Date:12/19/2014)... 2014 Research and Markets ( ... "Technology Innovations in Smart Fabrics (Technical Insights)" ... http://photos.prnewswire.com/prnh/20130307/600769 The Research ... a detailed assessment on technological advancements and market ... 1. The Smart Fabrics market is ...
Breaking Biology Technology:Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3Technology Innovations in Smart Fabrics (Technical Insights) 2
... April 13, 2012  The Large Urology Group Practice ... disputed a study published this week in the ... that the study grossly misrepresents the prevailing urological ... adopting evidence based clinical protocols. They pointed out ...
... Shire plc (LSE: SHP, NASDAQ: SHPGY ), the global ... April 26, 2012. Results press release will be ... 14:00 BST / 09:00 EDT, , Live ... and Graham Hetherington, Chief Financial Officer will host the investor and ...
... increases the likelihood that it will be possible to predict ... without having to measure every aspect of it. That in ... silicothe goal of the proposed Human Brain Projecta more realistic, ... a world of predictive biology," says Henry Markram, the senior ...
Cached Biology Technology:Urologists Debunk Misleading, Grossly Inaccurate Prostate Cancer Biopsy Study 2Urologists Debunk Misleading, Grossly Inaccurate Prostate Cancer Biopsy Study 3Urologists Debunk Misleading, Grossly Inaccurate Prostate Cancer Biopsy Study 4Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012 2Data mining opens the door to predictive neuroscience 2
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition ... individuals. Facial recognition system measures the overall facial ... edges, mouth, and the distance between eyes. Facial ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... May 31, 2012 - Traveling the western U.S. state of Nevada ... a "world of talk" about the beauty of Lake Tahoe and ... high in the Sierra Nevada Mountains. Determined to make the 11-mile ... toiling up one mountain and then another to no avail. But ...
... from three U.S. federal agencies and the White House, the ... Dr. Floyd Malveaux, expressed strong support for the government,s new ... The release of the new report came on the last ... is an outcome of the interagency Asthma Disparities Working Group, ...
... don,t need to spray weedkiller to remove the weeds between ... boiling water, steam or flaming will dispatch even the hardiest ... PhD project from the University of Copenhagen. Weeds can ... that each treatment is dosed correctly. Basically, every single ...
Cached Biology News:Wildfire and an example of its important link to the ecosystem 2Leading childhood asthma group supports federal asthma action plan to reduce disparities 2Blanch your weeds 2
...
BD Falcon Center-well 60 mm In Vitro Fertilization (IVF) Dish, nonembryotoxic, noncytotoxic, tissue-culture treated polystyrene. (20/sp, 500/ca) Packaging: 20 / sleeve, 500 / case ...
...
BD BioCoat Poly-D-Lysine/Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine and laminin....
Biology Products: